HUNTSVILLE — Gannet BioChem, a Huntsville-based specialty chemical contract development and manufacturing organization, announced the appointment of key executives following its recent acquisition by Ampersand Capital Partners.
The leadership team includes Nicholas Shackley as chief executive officer and Chris Edwards as chief financial officer. Additionally, longtime Gannet BioChem leader Dr. Tony Sander has been named chief operating officer.
“These leadership appointments mark an exciting new chapter for Gannet BioChem as an independent company,” said Melanie Fan, principal at Ampersand Capital Partners. “We are thrilled to welcome Nick and Chris to the leadership team, while continuing to collaborate with Tony in his expanded role.
“With their expertise and vision, this team is well-positioned to drive innovation and growth, strengthening our commitment to advancing biopharmaceutical and therapeutic products.”
Shackley brings more than 25 years of experience in pharmaceuticals and chemical manufacturing. His leadership is defined by a strong focus on business transformation, operational efficiency, and commercial growth. Previously, he served as senior vice president and chief commercial officer at Lupin Manufacturing Solutions, where he led sales, business development, strategic marketing, and product management.
Edwards was CFO at Solesis and has held global finance operations roles at Syneos Health, Convatec, and Bristol-Myers Squibb.
A key leader at Gannet BioChem since 2003, Sander has more than 30 years of experience in chemical and API manufacturing, overseeing manufacturing and site operations at the Huntsville facility.
Gannet BioChem is showcasing its capabilities at DCAT (Drug, Chemical & Associated Technologies Association) 2025 this week, where company leaders and representatives will engage with global partners to discuss growth opportunities and innovation in polyethylene glycol (PEG) reagent manufacturing.
“DCAT presents the perfect opportunity to highlight Gannet BioChem’s proven expertise in developing, scaling, and manufacturing PEG reagents while connecting with industry partners,” said Shackley. “We are eager to share our vision for the company’s continued growth and our commitment to supporting biopharmaceutical innovators worldwide.”
With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol reagents — essential components in advanced biopharmaceutical and therapeutic products.
Operating from a state-of-the-art 124,000 square-foot facility near downtown Huntsville, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics.
Don’t miss out! Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
